256 related articles for article (PubMed ID: 30796625)
1. Ethambutol-Loaded Solid Lipid Nanoparticles as Dry Powder Inhalable Formulation for Tuberculosis Therapy.
Nemati E; Mokhtarzadeh A; Panahi-Azar V; Mohammadi A; Hamishehkar H; Mesgari-Abbasi M; Ezzati Nazhad Dolatabadi J; de la Guardia M
AAPS PharmSciTech; 2019 Feb; 20(3):120. PubMed ID: 30796625
[TBL] [Abstract][Full Text] [Related]
2. Microparticles containing erlotinib-loaded solid lipid nanoparticles for treatment of non-small cell lung cancer.
Bakhtiary Z; Barar J; Aghanejad A; Saei AA; Nemati E; Ezzati Nazhad Dolatabadi J; Omidi Y
Drug Dev Ind Pharm; 2017 Aug; 43(8):1244-1253. PubMed ID: 28323493
[TBL] [Abstract][Full Text] [Related]
3. The development of dimple-shaped chitosan carrier for ethambutol dihydrochloride dry powder inhaler.
Ahmad MI; Ungphaiboon S; Srichana T
Drug Dev Ind Pharm; 2015 May; 41(5):791-800. PubMed ID: 24694185
[TBL] [Abstract][Full Text] [Related]
4. Development of dry powder inhaler formulation loaded with alendronate solid lipid nanoparticles: solid-state characterization and aerosol dispersion performance.
Ezzati Nazhad Dolatabadi J; Hamishehkar H; Valizadeh H
Drug Dev Ind Pharm; 2015; 41(9):1431-7. PubMed ID: 25220930
[TBL] [Abstract][Full Text] [Related]
5. Development, In Vitro Characterization, Antitumor and Aerosol Performance Evaluation of Respirable Prepared by Self-nanoemulsification Method.
Naseri N; Zakeri-Milani P; Hamishehkar H; Pilehvar-Soltanahmadi Y; Valizadeh H
Drug Res (Stuttg); 2017 Jun; 67(6):343-348. PubMed ID: 28288490
[TBL] [Abstract][Full Text] [Related]
6. Rifampicin loaded chitosan nanoparticle dry powder presents an improved therapeutic approach for alveolar tuberculosis.
Rawal T; Parmar R; Tyagi RK; Butani S
Colloids Surf B Biointerfaces; 2017 Jun; 154():321-330. PubMed ID: 28363192
[TBL] [Abstract][Full Text] [Related]
7. Preparation and evaluation of inhalable dry powder containing glucosamine-conjugated gefitinib SLNs for lung cancer therapy.
Satari N; Taymouri S; Varshosaz J; Rostami M; Mirian M
Drug Dev Ind Pharm; 2020 Aug; 46(8):1265-1277. PubMed ID: 32594775
[TBL] [Abstract][Full Text] [Related]
8. Bedaquiline containing triple combination powder for inhalation to treat drug-resistant tuberculosis.
Rangnekar B; Momin MAM; Eedara BB; Sinha S; Das SC
Int J Pharm; 2019 Oct; 570():118689. PubMed ID: 31513868
[TBL] [Abstract][Full Text] [Related]
9. [Development of Inhalable Dry Powder Formulations Loaded with Nanoparticles Maintaining Their Original Physical Properties and Functions].
Okuda T
Yakugaku Zasshi; 2017; 137(11):1339-1348. PubMed ID: 29093369
[TBL] [Abstract][Full Text] [Related]
10. Solid Lipid Nanoparticle assemblies (SLNas) for an anti-TB inhalation treatment-A Design of Experiments approach to investigate the influence of pre-freezing conditions on the powder respirability.
Maretti E; Rustichelli C; Romagnoli M; Balducci AG; Buttini F; Sacchetti F; Leo E; Iannuccelli V
Int J Pharm; 2016 Sep; 511(1):669-679. PubMed ID: 27473279
[TBL] [Abstract][Full Text] [Related]
11. The safety of ethambutol dihydrochloride dry powder formulations containing chitosan for the possibility of treating lung tuberculosis.
Ahmad MI; Nakpheng T; Srichana T
Inhal Toxicol; 2014 Dec; 26(14):908-17. PubMed ID: 25472479
[TBL] [Abstract][Full Text] [Related]
12. Montelukast-loaded nanostructured lipid carriers: part II pulmonary drug delivery and in vitro-in vivo aerosol performance.
Patil-Gadhe A; Kyadarkunte A; Patole M; Pokharkar V
Eur J Pharm Biopharm; 2014 Sep; 88(1):169-77. PubMed ID: 25078860
[TBL] [Abstract][Full Text] [Related]
13. High dose dry powder inhalers to overcome the challenges of tuberculosis treatment.
Momin MAM; Tucker IG; Das SC
Int J Pharm; 2018 Oct; 550(1-2):398-417. PubMed ID: 30179703
[TBL] [Abstract][Full Text] [Related]
14. Dry powder formulation of kanamycin with enhanced aerosolization efficiency for drug-resistant tuberculosis.
Momin MAM; Sinha S; Tucker IG; Doyle C; Das SC
Int J Pharm; 2017 Aug; 528(1-2):107-117. PubMed ID: 28583333
[TBL] [Abstract][Full Text] [Related]
15. Dry-Powder Inhaler Formulation of Rifampicin: An Improved Targeted Delivery System for Alveolar Tuberculosis.
Rawal T; Kremer L; Halloum I; Butani S
J Aerosol Med Pulm Drug Deliv; 2017 Dec; 30(6):388-398. PubMed ID: 28510480
[TBL] [Abstract][Full Text] [Related]
16. Advanced spray dried proliposomes of amphotericin B lung surfactant-mimic phospholipid microparticles/nanoparticles as dry powder inhalers for targeted pulmonary drug delivery.
Gomez AI; Acosta MF; Muralidharan P; Yuan JX; Black SM; Hayes D; Mansour HM
Pulm Pharmacol Ther; 2020 Oct; 64():101975. PubMed ID: 33137515
[TBL] [Abstract][Full Text] [Related]
17. Pharmaceutical formulation of a fixed-dose anti-tuberculosis combination.
Danckwerts MP; Ebrahim S; Pillay V
Int J Tuberc Lung Dis; 2003 Mar; 7(3):289-97. PubMed ID: 12661846
[TBL] [Abstract][Full Text] [Related]
18. Phospholipid-based pyrazinamide spray-dried inhalable powders for treating tuberculosis.
Eedara BB; Tucker IG; Das SC
Int J Pharm; 2016 Jun; 506(1-2):174-83. PubMed ID: 27091294
[TBL] [Abstract][Full Text] [Related]
19. Inhalable spray-dried formulation of D-LAK antimicrobial peptides targeting tuberculosis.
Kwok PC; Grabarek A; Chow MY; Lan Y; Li JC; Casettari L; Mason AJ; Lam JK
Int J Pharm; 2015 Aug; 491(1-2):367-74. PubMed ID: 26151107
[TBL] [Abstract][Full Text] [Related]
20. Formulation, optimization, and characterization of rifampicin-loaded solid lipid nanoparticles for the treatment of tuberculosis.
Chokshi NV; Khatri HN; Patel MM
Drug Dev Ind Pharm; 2018 Dec; 44(12):1975-1989. PubMed ID: 30058392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
